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Introduction 
   Pulmonary fibrosis can be described as 
an excessive amounts of fibrous 
connective lung tissue in the lung. 
Idiopathic pulmonary fibrosis(IPF) is the 
most common form of interstitial lung 
disease(ILD).  When an obvious cause 
cannot be determined, a diagnosis of 
Idiopathic pulmonary fibrosis is made. 
The mean survival for patients is 
approximately 3-5 years from time of 
diagnosis.  IPF is found primarily in men 
over 50 years of age, with a history of 
cigarette smoking with concurrent 
environmental and occupational 
inhalation exposures(Leslie, 2011, p. 
592).  Pulmonary fibrosis has been 
identified by early pathologists at the 
beginning of the last century.  During 
autopsy, the signature “honeycombing” 
of a shrunken, cystic and fibrotic lungs 
were first identified. 
   IPF was first thought to an 
inflammatory disorder which was 
treated with corticosteroids and 
cytotoxic medications.  New 
understanding of IPF and the 
pathophysiology have shaped new 
treatments.  “Current concepts suggest 
that the disease results from aberrant 
reparative response to alveolar 
epithelial cell injury characterized by 
migratory proliferation, activation of 
fibroblasts and secretion of excessive 
amounts of extracellular matrix 
components, leading to scarring of the 
lungs, architectural distortion, and 
irreversible loss of function” 
(Tzouvelekis, Bonella & Spagnolo, 2015, 
p.359).  Working on a vascular thoracic 
floor, many patients are admitted with a 
diagnosis of IPF. 
 Presentation of 
Case 
  A 76 year old man was admitted with 
complaints of increased shortness of 
breath and is now requiring increased 
amounts of home oxygen.  He is having 
an elective VATS (video-assisted 
thorascopic surgery) lung biopsy which 
showed interstitial pneumonitis.  Since 
he has no acute (medicine, radiation) or 
identifiable cause for pulmonary 
fibrosis, he is diagnosed with idiopathic 
pulmonary fibrosis.  Due to his advanced 
age he is not a candidate for lung 
transplantation(Sheppard, 2013, p. 
1055).  What treatment is available for 
this patient?  What is his prognosis? 
What will be his disease progression? 
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Signs and 
Symptoms of IPF 
. 
• Nurses with updated evidence 
based practice information on IPF 
can be an invaluable source of 
education for patients and family. 
 
• New theories about IPF would 
contradict recent nursing 
education and treatment of 
patients 
 
• Studies have been undertaken in 
recent years show pulmonary 
rehabilitation has been effective 
in COPD patients, but the benefit 
has been less clearly shown with 
IPF measured by levels of activity 
and health care quality of life 
(Gaunaurd, et al., 2014, p. 1872). 
 
• With no curative or many 
treatment options, any 
rehabilitation should be studied. 
• 2014 study of 21 IPF patients in a 
randomized control trial between 
groups of organized pulmonary 
rehab versus a control group of 
no organized rehab showed 
“those pulmonary rehabilitation 
benefits patients with IPF by 
enhancing their level of physical 
activity and by significantly 
reducing the disease’s symptom 
burden” (Gaunaurd, et al., 2014, 
p. 1878). 
 
 
 
   According to the National Lung, Heart 
and Blood Institute (2011), the most 
common symptom of IPF is shortness of 
breath.  Initially a patient will have 
shortness of breath with exercise, but as 
the disease progresses a patient with have 
shortness of breath at rest.  The other late 
and secondary symptoms are: increased 
breathing rate, unintended weight loss, 
fatigue, malaise, aching muscles and or 
joints, and clubbing of the fingers.  IPF 
causes scarring and symptoms similar to 
other common lung ailments such as COPD 
(Chronic Obstructive Pulmonary Disease), 
so early and correct diagnosis are very 
important to patients and families.   
   Imaging will show traction 
bronchiectasis, thickening interlobular 
septae, and sub pleural honeycombing.  
When all the three above are present with 
no connective tissue disease or 
environmental exposure, then a confident 
diagnosis of IPF can be made (Noble, 
Barkauskas, and Jians, 2012, p. 2756).   
 
Misdiagnosis 
  Until recently, idiopathic pulmonary 
fibrosis was misdiagnosed and treated 
with medications which did not improve 
the prognosis.  Improvement of 
understanding of IPF has led to the first 
approved drugs to slow the progression of 
the disease.  Studies have been performed 
looking at medication and pulmonary 
rehabilitation to improve quality of life and 
outcomes for pulmonary fibrosis patients. 
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Conclusion  
• IPF can be similar in symptoms and 
presentation with other lung 
diseases 
• The sooner IPF can be diagnosed 
has been shown to reduce stress 
reported by patients with IPF 
(Duck, et al., 2014, p. 1055). 
• IPF is rare when compared to COPD, 
care must be taken to differentiate 
between the two diseases 
• Time is critical for IPF patients to be 
evaluated for possible lung 
transplantation.  New drugs and 
interventions need to be studied in 
this population 
• Pathophysiological understanding 
of this disease has lead to exciting 
treatments and most of all some 
hope for patients and families 
dealing with this terrible diagnosis 
 
Underlying Pathophysiology of IPF 
• Tyrosine Kinase is just one 
isolated factor released in the 
complicated pathophysiology of 
IPF 
 
• “The factors promote 
mesenchymal expansion and 
activation, leading to 
accumulation of matrix-
producing and invasive 
fibroclasts and myofibroclasts” 
(Noble, et al., 2012, p. 2759). 
 
• Mesenchymal expansion and 
destruction leads to the 
distinctive honeycombing effect 
of pulmonary fibrosis and poor 
oxygen/carbon dioxide exchange 
in alveolar cells.   
 
• The damage is non-reversible and 
leads to the poor prognosis 
associated with IPF 
 
 
• Three studies published in 2014 
showed when patients were given 
either nintedanib or pierfenidone 
had significant lower rate of 
decline of FVC versus patients 
receiving placebo at 52 weeks 
(Mandel et al., 2014, p. 117). 
 
• The research shows the first 
substantial medical treatment of 
IPF 
 
• Results of the three studies must 
be examined and looked at much 
closer 
 
• Even with exciting research 
results two limitations identified 
by the study authors need to be 
taken into account 
 
• First, the studies did not look at 
the beneficial effects past 52 
weeks or the effect on mortality 
and morbidity 
• Second, the authors caution both 
drugs do not cure IPF, only 
slowing the progression of the 
disease 
• The hope would be slower 
progression of the disease will 
help lead to more time to find a 
lung transplant donor for 
patients with IPF. Lung 
transplant is the only known 
curative treatment today 
   “Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease with 
few therapeutic options.  Apoptosis of alveolar cells, followed by 
abnormal tissue repair characterized by hyperplastic epithelial cell 
formation, is a pathogenic process that contributes to the 
progression of pulmonary fibrosis.  However the signaling 
pathways responsible for increased proliferation of epithelial cells 
is poorly understood”(Weng et al. 2014, p. 1402).   
IPF has been linked to: 
 
  * Cigarette smoking 
  * Environmental exposures 
  * Pharmacological Side effects 
  * Medical Diseases  
  * Virus or microbes 
 
   Understanding of role of the initial 
injury and the subsequent aberrant 
cellular repair has opened up new 
theories and treatments for IPF.  
Multiple studies have been 
undertaken to find a singular 
response to the initial injury, but 
multiple cell and responses may be 
in play with IPF(Ryu, et al, 2014, p. 
1132). 
 
Genetic 
transmission 
 
• Genetics transmission may 
happen in 5% of all IPF cases 
• Transmission is autosomal 
dominant with variable and 
reduced penetrance.   
• Genetics studies have 
identified mutations only 
expressed in lung epithelial 
cells(Noble et al., 2012, p. 
2757). 
• A specific gene, MUS5B has 
been identified in 38% of 
patients with IPF 
• MUS5B is only expressed in 
bronchiolar, not epithelial cells 
but the discovery shows 
possibility of biomarkers 
(Flynn, Baker, & Kass, 2015, p. 
21). 
• Mormon death certificate 
database may show larger 
genetic component(Scholand, 
Coon, Wolff, & Cannon-
Albright, 2013, p. 480) 
 
 
 
Updated Theories 
of IPF  
  
“Several lines of evidence have 
emerged implicating a combination of 
environmental, age-related and genetic 
factors that coalesce to create alveolar 
epithelium that is susceptible to injury 
from either unknown endogenous 
factors or exogenous insults such as 
viral infection or micro aspiration” 
(Noble, et al., 2012, p. 2758). 
 
Tyrosine Kinase 
Role in IPF 
 
• Epithelium-mesenchymal cross talk 
and destruction of mesenchymal 
expansion shows the attempt to 
repair damage by alveolar 
epithelial type 2 cells (AE2C) that 
release growth factors, cytokines 
and coagulants.  Tyrosine kinase 
has been linked to IPF in recent 
studies (Noble, et al., 2012, p. 
2759). 
 
• The discovery of the role of 
tyrosine kinase in IPF has led to the 
development of the first FDA 
approved drugs in 2014  
 
• Tyrosine kinase inhibitors: 
Nintedanib and Pirfenidone 
 
